Wuhan YZY Biopharma Co. Ltd. is out-licensing lead candidate M-701, a CD3/EpCAM bispecific antibody, to Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ) for China rights in a deal worth up to ...
It is administered through Intravenous route. The therapeutic candidate acts by targeting T-cell immunoglobulin mucin domain 3 (TIM-3). Chia Tai Tianqing Pharmaceutical Group (CTTQ) subsidiary of Sino ...